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Abstract
Background: Children with cerebral palsy (CP) often have an altered gait. Orthopaedic surgery, spasticity management,
physical therapy and orthotics are used to improve the gait. Interventions are individually tailored and are
planned on the basis of clinical examinations and standardised measurements to assess walking (‘care as usual’).
However, these measurements do not describe features in the gait that reflect underlying neuro-musculoskeletal
impairments. This can be done with 3-dimensional instrumented gait analysis (IGA). The aim of this study is to test the
hypothesis that improvements in gait following individually tailored interventions when IGA is used are superior to
those following ‘care as usual’.
Methods/Design: A prospective, single blind, randomised, parallel group study will be conducted. Children aged 5
to 8 years with spastic CP, classified at Gross Motor Function Classification System levels I or II, will be included. The
interventions under investigation are: 1) individually tailored interdisciplinary interventions based on the use of IGA, and
2) ‘care as usual’. The primary outcome is gait measured by the Gait Deviation Index. Secondary outcome measures are:
walking performance (1-min walk test) and patient-reported outcomes of functional mobility (Pediatric Evaluation of
Disability Inventory), health-related quality of life (The Pediatric Quality of Life Inventory Cerebral Palsy Module) and
overall health, pain and participation (The Pediatric Outcome Data Collection Instrument). The primary endpoint for
assessing the outcome of the two interventions will be 52 weeks after start of intervention. A follow up will also be
performed at 26 weeks; however, exclusively for the patient-reported outcomes.
Discussion: To our knowledge, this is the first randomised controlled trial comparing the effects of an individually
tailored interdisciplinary intervention based on the use of IGA versus ‘care as usual’ in children with CP. Consequently,
the study will provide novel evidence for the use of IGA.
Trial registration: Trial registration: ClinicalTrials.gov NCT02160457. Registered June 2, 2014.
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Background
Cerebral palsy (CP) is a diagnosis that includes a range
of conditions caused by a non-progressive brain injury
occurring in the developing foetal or infant brain. Al-
though the brain injury is non-progressive, the neuro-
musculoskeletal and movement-related functions may
deteriorate and cause activity limitation [1]. Most children
with CP exhibit an altered gait such as stiff knee gait,
crouch gait, excessive hip flexion, intoeing or equinus [2].
Thirty-eight to sixty-five per cent of all children with CP
walk independently and are consequently classified on the
Gross Motor Function Classification System (GMFCS) at
level I or II [3, 4].
The interdisciplinary interventions addressing impair-
ments that affect the patients’ gait can be described in
four categories: orthopaedic surgery, spasticity manage-
ment, physical therapy and orthotics [5, 6]. Guided by
the problems faced by each child with CP, interventions
should be individually planned to help the child and
family to achieve their goals [6].
In Denmark, a patient-centred and evidence-based ap-
proach is pursued. An adapted version of the Swedish
Cerebral Palsy follow-Up Program is used, where the
healthcare professionals use standardised examinations
of the child throughout childhood [7]. A local team,
which usually consists of a paediatrician, a paediatric
orthopaedic surgeon and a physiotherapist, is respon-
sible for the follow up and individually tailored interdis-
ciplinary interventions for each child with CP. The local
team meets with the child and family once or twice a year
to examine the child’s development and to plan and coord-
inate common goals and interventions for the child. As part
of the Cerebral Palsy follow-Up Program, the overall gross
motor function and walking performance are evaluated by
standardised measures such as the GMFCS, the Functional
Mobility Scale and sometimes the Gross Motor Function
Measure (GMFM) [8–10]. However, objective features in
the gait that reflect underlying neuro-musculoskeletal
impairments are not described. This can be done with
3-dimensional instrumented gait analysis (IGA).
The purpose of IGA is to provide objective and valid
measures of gait in three planes [11]. With the use of
infrared camera technology and force plates embedded
in the floor, it is possible to determine joint movement
(kinematics), joint torque and power (kinetics) and
tempo-spatial parameters. IGA thus provides a large
amount of interdependent data and variables corre-
sponding to different gait pathologies.
The quantity and complexity of data have led to the
description of different indices that quantify a part of, or
the overall, gait pathology into a single score. For ex-
ample, the Gait Deviation Index (GDI) [12], and Gait
Profile Score [13] summarise the overall gait into a sin-
gle score for each patient, whereas the Gait Variable
Score is an index for a single gait variable rather than a
single score for all variables [13].
The use of IGA in combination with clinical examina-
tions and standardised measures provide quantifiable in-
formation for clinical decisions regarding individually
tailored interventions, in contrast to the current practice
(‘care as usual’) where only clinical examinations and
standardised measures are used. In the last two decades,
pre-operative IGA has developed to the point where it has
become an important investigation in ambulant children
with CP [11, 14, 15]. Studies have shown that IGA can sig-
nificantly affect the decisions regarding orthopaedic surgical
interventions [16–18], and that there is good agreement
between recommendations based on IGA and the surgery
performed [19]. The effects of individually defined physio-
therapy in children with CP based on clinical examinations
and IGA have been investigated in a prospective double
blind cross-over study [20]. The authors observed a
superior effect of individually defined physiotherapy on
achievement of treatment goals, gross motor function and
some selected gait parameters compared with a generic
training program. The use of IGA per se has only been
investigated in relation to decision-making in orthopaedic
surgery and effects of individually defined physical therapy.
To our best knowledge, the potential added benefit of
using IGA in the decision-making of interdisciplinary
interventions directed towards impairments in gait has not
been investigated in children with CP. Thus, a study inves-
tigating potential difference in improvements in overall gait
pathology following individually tailored interdisciplinary
intervention with or without IGA is needed. The aim
of this study is to determine which of two modalities
(i.e. individually tailored interdisciplinary intervention with
or without IGA) leads to greater improvements in the
overall gait pathology, walking performance and patient-
reported outcomes of functional mobility, overall health,
pain and participation in normal daily activities and
health-related quality of life after 52 weeks. However,
it is important to note that the study is not intended to
document the effect of IGA alone, but to document the dif-
ference in the effects of the interdisciplinary interventions,
when IGA is implemented in the experimental group.
The primary hypothesis to be tested is:
H1) The use of IGA in the planning of individually
tailored interdisciplinary interventions will be more
effective in improving overall gait pathology (evaluated by
GDI (primary outcome)) compared with ‘care as usual’ in
children with CP at GMFCS levels I and II.
The secondary hypotheses are:
H2) The use of IGA in the planning of individually tailored
interdisciplinary interventions will be more effective
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compared with ‘care as usual’ in improving walking
performance (1-min walk test) and patient-reported
outcomes of functional mobility (Pediatric Evaluation of
Disability Inventory), overall health, pain and participation
in normal daily activities (Pediatric Outcomes Data
Collection Instrument) as well as health-related quality of
life (Pediatric Quality of Life Inventory Cerebral Palsy
Module) in children with CP at GMFCS levels I and II.
Furthermore, a number of hypothesis-generating
analyses will be performed on the effects of the two
modalities on the following explorative outcomes: gait,




A prospective, single blind, parallel group, balanced ran-
domisation [1:1] study will be conducted in accordance
with guidelines of the CONSORT statement [21, 22]. The
experimental design and outcome measures are depicted
in Fig. 1 and design considerations are outlined in Table 1.
The current study complies with the principles of the
Declaration of Helsinki. Ethics approval has been obtained
from the Committee for Medical Research Ethics in the
Region of Southern Denmark (S-20120162) and the
Danish Data Protection Agency (2008-58-0035). Trial
registration: ClinicalTrials.gov NCT02160457. Registered
June 2, 2014, Update June 6, 2014.
Participants and study setting
Participants in the Cerebral Palsy follow-Up Program in
the Region of Southern Denmark and the North Denmark
Region will be screened for eligibility according to inclusion
and exclusion criteria described below. Written information
about the study will be provided to parents and physiother-
apists of eligible children by the principal investigator
(HMR). Subsequently, oral information will be given to the
parents of eligible children, and for those who are inter-








From the Cerebral Palsy follow-Up Program
Not eligible or not interested:
No further contact
Screening for eligibility
Screening of all the children followed by the 
same physiotherapist
Baseline assessment (n = 60)
Patient characteristics, primary, secondary and 








Individually tailored interdisciplinary 
intervention based on IGA









26 week follow up
Patient-reported outcome measures
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52 weeks after start of intervention
Primary, secondary and explorative 
outcome measures
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52 weeks after start of intervention








Fig. 1 Flow diagram for the trial. The flow diagram presents an overview of the progress through the phases of the trial
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further information about the study. Written consent to
participate will be obtained prior to the baseline test.
Eligible participants are children aged 5 to 8 years
diagnosed with spastic CP, classified at Gross Motor
Function Classification System levels I or II. Exclusion
criteria are: earlier interventions in the form of ortho-
paedic surgery within the past 52 weeks, injection with
botulinum toxin type A in the 12 weeks prior to baseline
assessments, and relocation to another region during the
trial. Furthermore, a child will be excluded if he/she is not
able to demonstrate sufficient co-operation and cognitive
understanding to participate in the IGA.
This study involves six hospital units in the two regions,
and the Orthopaedic Research Unit at the University of
Southern Denmark. The results from the initial examin-
ation, IGA and outcome measures will be collected at the
Motion Analysis Laboratory at Odense University Hospital.
Patient-reported outcome questionnaires will be mailed to
the parents of the participants. Interdisciplinary interven-
tions in both groups will be conducted by the local
teams at the six hospital units (paediatricians and
paediatric orthopaedic surgeons) and in the 33 muni-
cipality units (physiotherapists) in the two regions.
During the study period, all participants will remain in the
Cerebral Palsy follow-Up Program and will receive
individually tailored interdisciplinary interventions as
part of the public health care system.
Intervention
The study interventions will be carried out in two study
groups:
– Experimental: Individually tailored interdisciplinary
intervention based on measures performed as part
of the Cerebral Palsy follow-Up Program, other
clinical examinations AND IGA.
– Control: Individually tailored interdisciplinary
intervention based on measures performed as part
of the Cerebral Palsy follow-Up Program and other
clinical examinations BUT NOT IGA (‘care as usual’).
The two models of individually tailored interdisciplinary
intervention are outlined in Fig. 2. The trial is not
designed to distinguish between the different elements
in the two intervention groups.
For both the experimental and control groups, the
interdisciplinary interventions addressing impairments
that affect the patients’ gait, can be described in four
categories [5, 6]:
– Orthopaedic surgery, such as tendon transfer, muscle
tendon lengthening, rotational osteotomy and
stabilisation of joints that aim to restore joint
mobility, muscle function, stability and lever arm
dysfunction [23].
– Spasticity management, where the most frequently
used intervention is injection of botulinum toxin
type A in muscles with increased muscle tone in the
lower extremities [24].
– Physical therapy such as goal-directed training or
functional training of specific elements of the gait or
walking [6].
– Orthotics, such as ankle-foot orthoses that provide
stability and/or mobility of the joints and/or support
muscle function [25].
The study will not involve standardisation of the inter-
disciplinary intervention and will not provide training in
Table 1 Design considerations. Considerations regarding the design of the study and the participants/children
Issue of consideration Impact on study design
Compliance by patients, families and practitioners for
the recommended interdisciplinary interventions
Patients and families
Parents and the local team will receive the gait analysis report
where the impairments are outlined and the recommendations are explained.
Practitioners
The local team will be contacted and given the opportunity to ask
questions about the report and recommendations.
Risk of noncompliance with intervention amongst practitioners
who are responsible for healthcare for two or more participants.
Physical therapy First randomised patient will undergo randomisation as described.
The remaining patients followed by the same physiotherapist will be given the
same allocation.
Orthopaedic surgery, spasticity management, orthotics
Relatively few practitioners carry out these interventions; therefore it is not possible
to take into account the risk of noncompliance with the intervention amongst
practitioners.
Synchronisation of interventions Gradually, it could be assumed that methods/knowledge/attention introduced
by the IGA will influence the control group. This will be evaluated post-hoc via a
comparison of interventions used in the control group in the first 6 months of
the study with the interventions used in the last 6 months of the study.
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the interventions provided by the participating hospitals
and municipalities. This is to ensure a pragmatic approach
to reflect common practice and ensure high external
validity of the study.
Experimental
The experimental intervention will include an individually
tailored interdisciplinary intervention based on clinical
examinations, standardised measurements of walking and
recommendations for interventions based on knowledge
about the impairments that affects the gait from IGA. An
interdisciplinary team will provide recommendations for
interventions based on impairment-focused interpretation
and reporting according to Baker 2013 [26]. The data col-
lection, interpretation, development of recommendations
and dissemination of recommendations will be carried out
in four steps:
Step 1: Instrumented gait analyses (data collection)
Instrumented gait analysis including clinical examin-
ation, sagittal and coronal plane video recording and
3-dimensional kinematics and kinetics will be carried
out. An 8-camera Vicon T40 system (Vicon, Oxford, UK)
operating at 100Hz will be used for data collection.
Ground reaction forces will be recorded using two
force plates (AMTI, OR6-7-1000, Watertown, MA,
USA), sampling at 1000Hz. The Plug-in Gait model,
Vicon Nexus Software (version 1.7.1 or later) and
Vicon Polygon software (version 3.5.2 or later) will be
used for data processing, to define gait cycles, spatio-
temporal parameters, kinematic and kinetic data [27].
The children will walk barefoot and, if relevant, also
with orthotics and shoes, at a self-selected speed along a
10-m walkway until at least five acceptable trials are
collected for each child. To validate the gait performance,
parents will be asked if the gait is representative of their
child’s normal walking.
Step 2 Impairment-focused interpretation The ap-
proach ‘Impairment-Focused Interpretation’ [26] refers
to the interpretation of the gait analysis. The principal
investigator (HMR) will identify and describe the impair-
ments that are affecting the child’s gait in a standardised
report and subsequently validate findings with the head
of the motion laboratory (AHL).
Step 3: Recommendations for interdisciplinary
interventions addressing impairments from IGA
The recommendations will address the impairments
found in the impairment-focused interpretation (Step 2)
and will be provided by the gait analysis team, which
will consist of a neuro-paediatrician (LKH), a paedi-
atric orthopaedic surgeon (NWP or VE), a physio-
therapist (HMR) and a biomechanist (AHL). To
facilitate an objective recommendation for treatment
selection based on treatment algorithms described by
Group 1 Experimental intervention Group 2 Control intervention (‘Care as usual’)
Individually tailored interdisciplinary intervention based on 
measures performed as part of the Cerebral Palsy follow-Up 
Program and other clinical examinations AND 
instrumented gait analysis
The instrumented gait analysis consists of four steps:
1 Instrumented gait analysis (data collection)
2 Impairment-Focused Interpretation
3 Recommendations for interdisciplinary 
interventions
4 Dissemination of recommendations
Individually tailored interdisciplinary interventions based on 
measures performed as part of the Cerebral Palsy follow-Up 
Program and other clinical examinations BUT NOT 
instrumented gait analysis.
Interventions
The interventions are individually tailored and after acceptance by 
child and family are carried out by the local team
Orthopaedic surgery Spasticity management Physical therapy Orthotics
Application of interventions
Category, duration and intensity of the 
applied interventions are recorded
Fig. 2 Models of individually tailored interdisciplinary interventions. This figure gives an overview of the two models of individually tailored interdisciplinary
interventions that are under investigation in the study
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Miller 2007 [28], we created a list of the most common
underlying neuro-musculoskeletal impairments of the
primary movement features found in IGA (see Table 2).
Finally, each of the recommendations for interdisciplinary
interventions will be based upon consensus. Otherwise,
the specific interventions will not be recommended.
Table 2 Considerations before recommending interdisciplinary interventions. To facilitate an objective recommendation for treatment
selection, we created a list of the most common underlying neuro-musculoskeletal impairments of the primary movement features
found in IGA. The table describes the primary segment of movement feature (column 1), underlying neuro-musculoskeletal impairment
(column 2–3) and the interdisciplinary interventions under consideration (column 4–7)
Primary segment of movement featureand underlying
neuro-musculoskeletal impairment
Interdisciplinary interventions under consideration
Orthopaedic surgery Spasticity management Physical therapy Orthotics
Pelvic
Altered range of movement in anterior/posterior tilt, caused by impairments in:
Body structures x
Muscle tone function x
Muscle power or endurance function x
Altered range of movement in pelvic obliquity, caused by impairments in:
Body structures (Limb length discrepancies) x x
Compensation for reduced control of movements x
Hip
Altered range of movement in flexion/extension, caused by impairments in:
Body structures x x
Muscle tone function x
Muscle power or endurance function x x
Altered range of movement in abduction/adduction, caused by impairments in:
Body structures x x
Muscle tone function x
Muscle power or endurance function x x
Altered range of movement in rotation, caused by impairments in:
Body structures x
Muscle tone function x
Muscle power or endurance function x x
Compensation for reduced control of movements x
Knee
Altered range of movement in flexion/extension, caused by impairments in:
Body structures x x
Muscle tone function x
Muscle power or endurance function x x
Compensation for reduced control of movements x x
Ankle and foot progression
Altered range of movement in dorsi- or plantarflexion, caused by impairments in:
Body structures x x x
Muscle tone function x
Muscle power or endurance function x x
Altered range of movement in foot progression, caused by impairments in:
Body structures and/or function
(Tibial torsion, Planovalgus, Equinovarus))
x x
Compensation for reduced control of movements x x
Rasmussen et al. BMC Pediatrics  (2015) 15:202 Page 6 of 13
Step 4: Dissemination of recommendations to the
child, family and local team The parents of the child
and the local team, which consists of a paediatrician, a
paediatric orthopaedic surgeon, a physiotherapists and/
or an orthotist, will be informed about the recommenda-
tions for interventions based on knowledge from IGA.
To promote the application of the recommended inter-
vention from IGA, members of the local team will be
asked if they have any questions about the results of the
report and whether they will follow the recommenda-
tions. Furthermore, they will be asked which specific
goals they have set for the applied interventions.
Adherence to the recommended interventions is not a
prerequisite for participation in the study. As in daily
clinical practice, the child, his/her family and the local
team will have the option to follow or to reject the rec-
ommended intervention or to choose other interven-
tions than those recommended by the gait analysis team.
Control
The control intervention (‘care as usual’) will include
individually tailored interdisciplinary interventions based
on measures performed as part of the Cerebral Palsy
follow-Up Program and other clinical examinations, but
not the IGA.
Measurements
All patient characteristics and outcomes are listed in
Table 3. Patient characteristics, IGA and 1-min walk will
be performed at baseline and at 52 weeks post start of
intervention (primary endpoint). The patient-reported
outcome measures will be conducted at baseline, 26 weeks,
and 52 weeks post start of intervention. The time point
‘start of intervention’ is defined as the week where the re-
port is released. The data collection in the control group
will be adjusted according to the planned time points in
the experimental group. Furthermore, to acknowledge
that surgery might be influenced by a long planning phase
(i.e. consideration of surgery, involvement of patient and
family and planning) and rehabilitation, a second post
intervention examination will be performed at 52 weeks
post operation and included in a per protocol analysis.
In addition to the baseline data and classification, pri-
mary and secondary outcome measures, a range of explora-
tory outcome measures will be collected. The primary and
the secondary outcome measures will be used to confirm
or reject the described hypotheses, while the explorative
outcome measures will be used for hypothesis generation,
and to report other potential beneficial or harmful effects
of the interventions.
Baseline data and classification of function
The Gross Motor Function Classification System (GMFCS)
will be used to classify the child’s ability to carry out
self-initiated movements related to sitting and walking
[9]. The GMFCS has strong construct validity with the
Gross Motor Function Measure (GMFM) [29] and good
inter-observer and test-retest reliability with generalisabil-
ity coefficient values of 0.93 and 0.79 [30]. Furthermore,
the Functional Mobility Scale will be used to quantify the
child’s mobility according to the need for assistive devices
in different environmental settings [10]. Construct validity
has been investigated and inter-observer reliability with
agreement values of 0.86 to 0.92 with weighted kappa
coefficients have been shown [31, 32].
Primary outcome measure
Overall gait pathology IGA will be conducted as de-
scribed in Step 1: Instrumented gait analyses. Data from
five representative trials will be analysed. Both at baseline
and post intervention, the data collection will be done at a
self-selected walking speed. If the self-selected walking
speed on the two occasions differs more than 15 %, the
data collection will also be conducted at a walking speed
matched to that at baseline. A trained lab technician will
perform the data collection and data processing.
The primary outcome measure is the GDI, which is
based upon kinematic data from the IGA, and is an
overall quantitative index that summarises the overall
gait pathology into a single score for each patient by
comparison with non-pathological gait. A GDI value of
100 represents the absence of gait pathology, and each
10-point decrement below 100 indicates one standard
deviation from normal gait kinematics [12]. For the
primary outcome measure, the median of the five tri-
als for each leg will be used to calculate the average
of both legs to provide a single index for each child.
Since gait speed per se might affect GDI, the primary
outcome analysis will be based upon matched walking
speed, as described above.
Satisfactory concurrent and construct validity of the GDI
in children with CP have been shown [12, 33]. The GDI
has demonstrated excellent intra-rater reliability and ac-
ceptable agreement across two repeated sessions in children
with CP [34]. The responsiveness of GDI has been shown
by comparing the GDI score before and after surgical
lengthening of the gastrocnemius in children with CP [35].
Secondary outcome measures
Walking performance Walking performance will be
measured by using the 1-min walk test and will be
performed as described by McDowell et al. [36]. It
has demonstrated high correlation with gross motor
function [37] and good test-retest reliability with ICC
values of 0.94 for children with CP [36].
Functional mobility The Mobility Scale of the original
Pediatric Evaluation of Disability Inventory evaluates the
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child’s functional mobility in everyday activities with re-
gard to functional skills and amount of caregiver assist-
ance [38]. A Danish version will be applied as a parental
questionnaire: The content and discriminative validity
have been established in children with CP [39, 40].
Health-related quality of life The Pediatric Quality of
Life Inventory Cerebral Palsy Module is a measure of
health-related quality of life, specifically designed for
children with CP. It is based upon the parents’ report
and measures physical, emotional, social and school
functioning. Construct and discriminative validity of the
original version have been supported by comparing the
scores from children with CP with a generic measure of
the same construct with those from children without
disability. Satisfactory reliability with ICC values of 0.42
to 0.84 was demonstrated in the same study [41]. A lin-
guistically validated Danish version will be used [42].
Overall health, pain and participation The Pediatric
Outcomes Data Collection Instrument assesses overall
health, pain and participation in normal daily activities.
Concurrent and discriminant validity have been assessed
by comparing the Pediatric Outcomes Data Collection
Instrument with other measures of health and well-being,
gross motor function and diagnostic subgroups in children
with CP [43]. Moderate to good test-retest reliability
with ICC values of 0.71 to 0.97 has been reported in
children with orthopaedic or musculoskeletal disorders
[44]. The Pediatric Outcomes Data Collection Instrument
is currently being translated into Danish.
Exploratory outcome measures
Gait pathology Data from the IGA will be used to
calculate the median Gait Variable Score of the first five
trials for each leg at a self-selected walking speed and at
matched (pre and post) walking speed, to identify
changes in gait pathology at joint levels. The explorative
outcome measures based upon the Gait Variable Score
will be used for hypothesis-generation purposes.
Satisfactory face and criterion validity of the Gait
Variable Score in children with CP have been shown
[45]. Investigation of intra-session variability has suggested
that the Gait Variable Score is a reliable measure within
a single session [13]. Fair to good intra-rater reliability
and acceptable agreement across two repeated sessions
Table 3 Summary of measures to be collected. All patient characteristics and outcomes to be collected at baseline, 26 weeks and at
primary endpoint (52 weeks) are listed in the table
Instrument Baseline 26 weeks Primary endpoint
Baseline data and classification of function
Age (years) x
Ability to carry out self-initiated movements GMFCS x x
Functional mobility FMS x x
Height (cm) x x
Leg length (cm) x x
Primary outcome measure: Gait
Overall gait pathology GDI x x
Secondary outcome measures
Walking performance (metre) 1-min walk x x
Functional mobility PEDI x x x
Health-related quality of life PedsQL x x x
Overall health, pain and participation PODCI x x x
Explorative outcome measures
Walking performance, gait pathology, spatio-temporal parameters, and behaviour of health care providers
Gait pathology GVS x x
Step length and timeStride length and cadenceTime of single support for each leg
and double supportWalking speed
IGA x x
Family-centred behaviour of health care providers MPOC-20 x x x
Recommended and applied interventions
Categories of recommended interventions x
Categories of applied interventions x x
Abbreviations: GMFCS Gross Motor Function Classification System, FMS Functional Mobility Scale, IGA Instrumented gait analysis, GDI Gait Deviation Index,
1-min walk 1 min Walk Test, PEDI Pediatric Evaluation of Disability Inventory, PedsQL Pediatric Quality of Life Inventory Cerebral Palsy ModuleTM, PODCI Pediatric
Outcome Data Collection Instrument, GVS Gait Variable Score, MPOC-20 Measure of Processes of Care, CPUP Cerebral Palsy follow-Up Program
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have been shown for the Gait Variable Score in children
with CP [34].
Walking performance The following spatio-temporal
parameters from the IGA will be used:
1) Step length and time, and limb-to-limb asymmetry
index,
2) Stride length and cadence,
3) Time of single support for each leg and double
support, and limb-to-limb asymmetry index, and
4) Walking speed.
Intra-subject reliability of gait analysis in normal and
spastic children has been investigated. The study re-
ported acceptable coefficients of variation of 3.4 to 9.7 %
on spatio-temporal parameters in children with spastic
CP [46].
Family-centred behaviour of health care providers
Measure of Processes of Care is a self-report measure of
parents’ perception of the extent to which the health
services that their child receives are family-centred.
Concurrent validity has been investigated by comparison
with measures of satisfaction and stress. Discriminative
validity has been demonstrated by comparing Measure
of Processes of Care scores between different programs of
service delivery and acceptable reliability with Cronbach’s
alpha of 0.83 to 0.90 has been documented [47]. A Danish
version will be used [48].
Recommended and applied interventions Records of
the recommended and applied interventions will be
used to explore the type and number of interventions
in the two groups with regard to category (Orthopaedic
surgery, Spasticity management, Physical Therapy and
Orthotics).
Adverse events
Any adverse events that occur in the experimental
and control groups will be registered and reported in
accordance with the standards of the Danish Health
and Medicines Authority. Information about adverse
events will be gathered from parents of the partici-
pants, from the local teams and from the gait labora-
tory staff. Adverse events may occur as a direct result
of the study activities, such as a fall during the IGA
or indirectly as a result of the interdisciplinary inter-
ventions, such as pressure sores after casting. Any de-
tected adverse advents or unintended effects will be
reviewed by the principal study investigator (HMR)
and by a neuro-paediatrician (LKH). The events will
be listed and defined, with reference to standardised
criteria where appropriate.
Sample size
The sample size for this study is calculated to create
power for the primary hypothesis. The sample size
calculation is based upon the GDI (primary outcome),
collected as part of another study in our laboratory on a
comparable group of children with CP (mean GDI 79.3,
SD 12.0). A minimum clinically important difference in
GDI has been defined as 7.9 points by the current group
of authors a priori, which is equivalent to an improvement
of 10 %, as suggested by Swartz et al. [49] . A mini-
mum of 29 subjects in each group (n = 58) is required
with alpha = 0.05 and 80 % power. Following these
estimations, it was decided to include 60 children in
total (30 patients in each group), allowing for a drop-
out rate of 5 %.
Randomisation
After baseline assessment, children will be randomised
to either the ‘Experimental’ or the ‘Control’ group. The
randomisation will be stratified according to the physio-
therapist to whom the child is appointed. For children
who are followed by a physiotherapist, who is responsible
for two or more children, the first child randomised will
determine how the following children will be allocated.
Randomisation will be computer-generated by a re-
searcher with no other involvement in the study. Partici-
pants will be allocated by a sequence of numbers: 0 –
referring to ‘Experimental’, and 1 – referring ‘Control’.
The allocation sequence will be concealed in sequentially
numbered opaque, sealed envelopes. When all partici-
pants followed by the same physiotherapist have com-
pleted the baseline assessment the principal investigator
(HMR) will open the envelope and inform the child’s
parents and the local team about the allocation.
Blinding
Participants and the local team will not be blinded. Data
collectors and data analysts will be blinded.
Data and statistical analysis
Main comparative analyses between groups will be per-
formed using an intention-to-treat analysis (all cases
with available baseline data carried forward). Between-
group mean differences and 95 % confidence intervals
will be estimated with a linear model in which baseline
scores are entered as the only covariate [50, 51]. Model
specifications will depend on evaluation of distributional
properties of collected data and appropriate adaptation
of point estimate and variation indicators. Data analysis
will be performed on the groups of children randomised
first and for the whole group of children to explore any
differences with regard to whether a child was randomly
assigned to the intervention or followed another child in
the randomisation.
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Secondly, a per protocol analysis will be performed.
Proportional odds models will compare the difference
between the two groups based on the participant-perceived
response to treatment.
Discussion
To our knowledge, this is the first randomised con-
trolled trial investigating the effectiveness of an individu-
ally tailored interdisciplinary intervention addressing
impairments identified by IGA compared with ‘care as
usual’ in children diagnosed with CP. Such a trial is war-
ranted because IGA is widely used for orthopaedic surgi-
cal planning [11, 14, 15] and has been shown to affect
the decision-making in the planning of orthopaedic
surgery [18]. However, its effectiveness regarding gait
pathology, walking performance and patient-reported
outcomes of functional mobility, overall health, pain and
participation in normal daily activities as well as health-
related quality of life have never been investigated.
The IGA has been investigated for quality as a meas-
urement tool [12, 33, 35, 46, 52]. The current trial seeks
to investigate the effectiveness of the IGA when applied
in a clinical practice involving multiple steps such as
interdisciplinary interventions in regard to changes in
the overall gait pathology, walking performance and
patient-reported outcomes of functional mobility, overall
health, pain and participation in normal daily activities and
health-related quality of life after 52 weeks. Consequently,
the current trial uses a pragmatic approach and is
accordingly not designed to distinguish between the
different elements in the two intervention groups but
rather to reflect common practice and ensure high external
validity. This is in contrast to studies emphasising internal
validity that are carried out in an ‘ideal setting’ with highly
selected participants, practitioners and hospitals [21].
The randomised controlled trial design will be used to
assess potential benefits associated with the use of the IGA
in interdisciplinary interventions, and thereby, provide
novel evidence. The randomised controlled trial design is
considered the gold standard for a clinical trial, and pro-
vides the most reliable evidence on the efficacy of health-
care interventions [22]. The study can be used to support
the decision-making as to whether IGA should be applied
in routine daily practice to all children with spastic CP at
GMFCS levels I and II. Thus, the purpose of the study
warrants a pragmatic approach as opposed to a more
explanatory design. The key differences in the two
approaches can be described in terms of purpose, setting,
participants, intervention and outcomes [21], which will be
incorporated in the following sections of the discussion.
The study will be carried out in the Region of Southern
Denmark and the North Denmark Region. Participants
will be recruited through the local teams in the Cerebral
Palsy follow-Up Program, and will encourage attendance
among eligible children. The Cerebral Palsy follow-Up
Program makes it possible to gain information to make a
thorough description of the ‘reach’ of recruitment of par-
ticipants into the population of interest and to document
potential study composition differences across the stages
of the trial [22]. The relatively young age group has been
chosen to ensure inclusion of children at an early age, be-
fore the development of extensive and fixed deformities
that cause impairments and associated gait pathology [53].
To ensure good data quality from IGA, participants at
GMFCS levels I and II have been chosen. However, this
may impact the generalisability of findings.
To reflect the current clinical procedures in Denmark
and to emphasise external validity, the experimental
intervention will be carried out in five steps. Selected
practitioners, who are highly trained, are responsible for
the first three steps (Step 1: IGA, Step 2: Impairment-
focused interpretation, and Step 3: Recommendations for
interdisciplinary interventions). Both the selected practi-
tioners and the local team will be involved in the
remaining step (Step 4: Dissemination of recommenda-
tions) and planning of individually tailored interdisciplin-
ary interventions. Paediatric orthopaedic surgeons will
perform the orthopaedic surgical procedures while the
local teams will carry out other interventions in terms of
spasticity management, physical therapy and orthotics.
Consequently, only parts of the experimental intervention
(Steps 1,2 and 3) will be standardised and strictly enforced
by researchers responsible for the study, whereas the
remaining parts of the experimental interventions will be
performed through the collaboration of local teams, the
selected practitioners and the researchers. The local
teams, regardless of treatment group, will use their stand-
ard procedures in the interdisciplinary interventions.
There is a risk of poor adherence to the recommended
interventions by participants and local teams. This has
previously been reported in a randomised controlled
trial that investigated the impact of gait analysis on sur-
gical outcomes in ambulatory children with CP, where
less than half (42 %) of the IGA recommendations were
followed [54]. To improve understanding of the recom-
mended interventions from the IGA, members of the
local team will be asked if they have any questions about
the results of the report and whether they will follow the
recommendations. The identification of individually tai-
lored treatment goals has previously been used in studies
concerning physical therapy [55, 56] and orthopaedic
surgery [57] for children with CP. Studies have shown
that the approach can promote improvement in every-
day activities and gross motor function [55], and that the
approach resulted in goals that were more frequently
and smoothly implemented [56].
As for the majority of studies that involve interven-
tions that cannot be blinded, the current study design
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has a potential risk of non-compliance of participants
with the intervention they are randomised to. In this
study, there is a risk that participants randomised to the
control intervention (‘care as usual’) will benefit from
knowledge obtained by practitioners from participants in
the experimental intervention. However, since IGA is
only performed in our institution, no one will gain ac-
cess to the examination without our knowledge. Thus,
the risk of non-compliance is primarily believed to be at
the physiotherapist level. Consequently, as described above,
in cases where physiotherapists are responsible for the in-
terventions for two or more participants, the first rando-
mised patient will determine the allocation of the following
patients. The interventions performed at the level of ortho-
paedic surgery, spasticity management and orthotics will
be carried out by relatively few practitioners. Thus, it will
be easier to contain this risk and practitioners will simply
be requested to continue with their standard care for the
‘care as usual’ group. These professionals have taken part in
the IGA interpretations for a number of years. A conse-
quence of this set-up might be that the interventions in the
‘care as usual’ group could be influenced by the profes-
sional experience gained from previous interpretations of
the IGA.
We have chosen a follow-up period of 52 weeks. This
is done to balance the desire for a short follow up for
the interventions’ spasticity management and physical
therapy, while the effects of orthopaedic surgery and or-
thotics might take as long as 24 months to emerge [58].
A wide range of outcome measures has been used to
document the effectiveness of interventions in children
with CP [43, 44]. For this study, we have decided to
include assessments of body function and structure, ac-
tivity and participation levels from the International
Classification of Functioning, Disability and Health [59].
The primary outcome measure is at the level of ‘body
function’, where we use overall gait pathology classified
by the GDI as a measure of gait pattern functions that
are defined as functions of movement patterns associ-
ated with walking [59] and can be used to reflect the ex-
tent to which the goal of ‘better looking gait’ has been
reached [60]. Performance on the GDI was chosen as
the primary outcome rather than on the Gait Profile
Score, because it seems to be more sensitive to change
in children with a relatively mildly affected gait [13], as
expected with the study population of children at
GMFCS levels I and II. The gait pattern function has
been found to be one of the important domains for
youth with CP, parents and medical professionals, when
considering treatment outcomes [60].
The secondary outcome measures are a range of mea-
sures on the level of ‘activity and participation’. The
measures have been chosen to be relevant to the particular
group of children participating in the study. The Gait
Variable Score will be calculated to document changes in
the nine kinematic variables and will be used to document
explorative changes at the joint level. Thus, we have
chosen a wide range of outcome measures that covers all
levels of the International Classification of Functioning,
Disability and Health and seems relevant to participants,
their parents and the healthcare professionals.
One might argue that the Gross Motor Function
Measure [8] could be a relevant outcome measure. How-
ever, due to the time-consuming IGA procedure, it
would be difficult to motivate the children for further
examination and, consequently, difficult to achieve valid
output measures. Furthermore, there is a risk of a ceiling
effect when the Gross Motor Function Measure is used
for children at GMFCS level I after the age of five years,
due to their relatively high level of functioning.
The current trial will provide novel evidence for the
effects of an individually tailored interdisciplinary inter-
vention designed to address impairments identified by
IGA versus ‘care as usual’ in children with spastic CP. The
results of the trial will be submitted to peer-reviewed
journals for publication, irrespective of the outcome,
in accordance with the CONSORT statement for the
reporting of randomised controlled trials.
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